We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1254 for:    twelve
Previous Study | Return to List | Next Study

Twelve Transcatheter Mitral Valve Replacement (TMVR) Pilot Study

This study is currently recruiting participants.
Verified October 2017 by Twelve, Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02428010
First Posted: April 28, 2015
Last Update Posted: October 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Twelve, Inc.
  Purpose
Study to evaluate the safety and performance of the Twelve TMVR System

Condition Intervention
Mitral Valve Insufficiency Device: TMVR Implant

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Safety and Performance of the Twelve Transcatheter Mitral Valve Replacement System in Patients With Severe, Symptomatic Mitral Regurgitation

Further study details as provided by Twelve, Inc.:

Primary Outcome Measures:
  • Adverse Events [ Time Frame: 30 days ]
    Number of patients with adverse events associated with the delivery and/or implantation of the device


Secondary Outcome Measures:
  • Procedural Success [ Time Frame: Through 5 years ]
    Number of patients with successful TMVR implant

  • Reduction of MR [ Time Frame: Through 5 years ]
    Number of patients with a reduction of MR Grade


Estimated Enrollment: 10
Study Start Date: September 2014
Estimated Study Completion Date: July 2023
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
TMVR Implant
Device: TMVR Implant
Implantation of the Twelve TMVR System

Detailed Description:
The study is a prospective, multi-center, non-randomized trial to evaluate the safety and performance of the Twelve TMVR System in very high risk patients with severe, symptomatic mitral regurgitation.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Severe mitral regurgitation (MR Grade 3-4+)
  • Symptomatic mitral regurgitation (NYHA Class II-IV)
  • Trans-apical access deemed feasible by the treating physician
  • Native mitral valve geometry and size compatible with the Twelve TMVR

Key Exclusion Criteria:

  • Left ventricular ejection fraction (LVEF) < 20
  • Evidence of intracardiac mass, thrombus, or vegetation
  • Prior valve surgery or need for other valve surgery
  • Prior stroke within 4 weeks
  • Need for coronary revascularization
  • History of, or active, endocarditis
  • Renal insufficiency (Creatinine > 2.5 mg/dL)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02428010


Contacts
Contact: Craig Straley 650-503-5724 cstraley@twelvemed.com

Locations
Poland
John Paul II Hospital Recruiting
Krakow, Poland
Contact: Krzysztof Bartus, MD, PhD    +48 50 2294350    cool_chris@interial.pl   
Sponsors and Collaborators
Twelve, Inc.
Investigators
Study Director: Craig Straley Twelve, Inc.
  More Information

Responsible Party: Twelve, Inc.
ClinicalTrials.gov Identifier: NCT02428010     History of Changes
Other Study ID Numbers: CIP-1402
First Submitted: April 23, 2015
First Posted: April 28, 2015
Last Update Posted: October 11, 2017
Last Verified: October 2017

Additional relevant MeSH terms:
Mitral Valve Insufficiency
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases